Renalytix PLC
Company Profile
Business description
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.
Contact
2 Leman Street
LondonE1W 9US
GBRT: +44 2079338790
Sector
Healthcare
Stock type
Defensive
Industry
Health Information Services
Fiscal Year End
30 June 2026
Employees
47
Stocks News & Analysis
stocks
Meta earnings: Strong end to 2025 as AI monetization begins to show
stocks
Why doesn’t the market like the earnings from this US tech giant?
stocks
Our Tesla fair value increases meaningfully
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,164.80 | 94.40 | -1.02% |
| CAC 40 | 8,132.94 | 61.58 | 0.76% |
| DAX 40 | 24,558.14 | 248.68 | 1.02% |
| Dow JONES (US) | 48,946.66 | 124.90 | -0.25% |
| FTSE 100 | 10,216.72 | 44.96 | 0.44% |
| HKSE | 27,387.11 | 580.98 | -2.08% |
| NASDAQ | 23,639.57 | 45.55 | -0.19% |
| Nikkei 225 | 53,322.85 | 52.75 | -0.10% |
| NZX 50 Index | 13,423.18 | 74.57 | 0.56% |
| S&P 500 | 6,954.52 | 14.49 | -0.21% |
| S&P/ASX 200 | 8,869.10 | 86.00 | -0.96% |
| SSE Composite Index | 4,117.95 | 40.04 | -0.96% |